10-09-2020

Press release: First patient recruited in research study investigating the effects of Remune in combination with exercise in cancer patients

OSLO, NORWAY AND LUND, SWEDEN, June 29, 2020.

Smartfish AS announces today the initiation of a research study at University of Rochester to assess the impact of Remune in combination with exercise on physical function and cachexia-related symptoms in cancer patients. Remune has previously shown to be beneficial in the nutritional management of cancer. The study will include a total of 45 patients.

The main aim of the randomized interventional study is to clarify whether nutritional supplementation containing high levels of omega-3 fatty acids, vitamin D and protein has an effect on cachexia and weight loss in patients suffering from Non-Small Cell Lung Cancer (NSCLC) or gastrointestinal cancer. The study participants will follow a bi-daily regimen of Remune for twelve weeks, with or without a progressive resistance exercise program (EXCAP©), developed specifically for cancer patients. Additionally, the researchers will investigate whether concomitant intake of Remune improves physical performance and quality of life, as well as assess the long-term impact on relevant biomarkers.

“Cancer cachexia is a complex condition that is best managed by multimodal intervention and optimal nutrition is a cornerstone in the management of cancer cachexia. The fact that Smartfish’s Remune is chosen for this important study is a recognition of our high-quality and tasty targeted medical nutrition products that can impact the outcome for severely ill patients”, says Mozhgan Dorkhan, Chief Scientific Officer at Smartfish.

Remune has been used in two randomized, double-blinded, and placebo-controlled pilot trials in patients with COPD and NSCLC with cachexia. In these studies, Remune demonstrated improvement in fatigue and dyspnea and the outcome measures of cancer treatment respectively by enhancing the nutritional status in these patient groups.

To learn more about Smartfish’s trials in NSCLC patients – original study and in-depth analysis – and in COPD patients, please follow the links.


For more information, please contact
Mozhgan Dorkhan, Chief Scientific Officer of Smartfish, +46 731474331
Geir Harstad, CEO of Smartfish, tel + 46 763151160

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients and raw materials. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway. Smartfish’s main shareholders are Norwegian Investinor and Swedish Industrifonden.

Nyheter

20-08-2020

Smartfish welcomes Mari Rivelsrud as our interim International Product Specia ...

18-08-2020

Uno Viberg has been appointed Product Development- and Quality manager of Sma ...

12-06-2020

Press release: In-depth analysis of clinical trial results shows that Smartfi ...

11-06-2020

Press release: New study reports positive results for Smartfish product in pa ...

05-06-2020

Smartfish Annual Report 2019

24-05-2020

Smartfishdrikk kan forbedre embryokvaliteten hos par som gjennomgår IVF-behan ...

14-05-2020

Smartfish mot kommersielt gjennombrudd

24-04-2020

Rollen et sunt kosthold spiller for å støtte immunforsvaret

04-10-2019

Pressemelding: Smartfish starter utrulling av forbrukerhelseprodukter i Asia ...

09-09-2019

Press release: Smartfish initiates global collaboration with B. Braun, securi ...